Tirzepatide enhances insulin secretion in a glucose-dependent manner, suppresses glucagon secretion, and slows gastric emptying
Many providers start patients on 5 mg/mL vials for exactly this reason
However, these measures were often insufficient for achieving significant long-term body weight loss, and many patients experienced plateauing weight loss or struggled with weight regain after treatment discontinuation
Compounded tirzepatide storage: the exception that confuses everyone This is where the conversation gets complicated
Some patients find that spacing injections to every other week reduces the psychological burden of frequent needle use while still achieving meaningful weight reduction during the maintenance phase of treatment
However, it would be inappropriate to apply any specific numeric shelf-life figure to retatrutide in the absence of validated, compound-specific stability data